Results 191 to 200 of about 33,038 (222)

Denosumab in castration-resistant prostate cancer

The Lancet, 2012
Athanassios, Kyrgidis, Thrasivoulos-George, Tzellos   +1 more
openaire   +2 more sources

Olaparib for Metastatic Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2020
Bivas, Biswas, Sandip, Ganguly, Joydeep, Ghosh   +2 more
openaire   +8 more sources

Novel treatments for castration-resistant prostate cancer

European Journal of Cancer, 2011
The contemporary management of metastatic castration-resistant prostate cancer (mCRPC) is evolving dramatically. Understanding the biology of this disease, positive phase III studies and approvals for 4 novel agents in the US in 2010 and shortly in Europe have dramatically changed the therapeutic landscape.
openaire   +2 more sources

Castration-resistant prostate cancer

2016
SIMPSON MELANIE A, BARYCKI JOSEPH
openaire   +5 more sources

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs

Research and Reports in Urology, 2022
Silke Gillessen, Consuelo Buttigliero, Fabio Turco   +2 more
exaly  

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Lancet, The, 2021
Anthony Joshua, Andrew Martin, Michael Hofman   +2 more
exaly  

Treatment of Castrate-Resistant Prostate Cancer

Journal of Urology, 2013
openaire   +2 more sources

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Cancer Cell, 2020
Sumit Subudhi, Matthew Galsky, Gwenaelle Gravis   +2 more
exaly  

Castrate-Resistant Prostate Cancer

Oncology Times, 2008
openaire   +2 more sources

Clinical development of novel therapeutics for castration‐resistant prostate cancer

Ca-A Cancer Journal for Clinicians, 2012
William Oh, Matthew Galsky, Alexander Small   +2 more
exaly